Clinical Trial: Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridem
Brief Summary: The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.
Detailed Summary:
Sponsor: Ionis Pharmaceuticals, Inc.
Current Primary Outcome: VLDL apoC-III [ Time Frame: 92 Days ]
Original Primary Outcome: VLDL apoC-III [ Time Frame: 92 Days ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Ionis Pharmaceuticals, Inc.
Dates:
Date Received: February 6, 2012
Date Started: February 2012
Date Completion:
Last Updated: June 14, 2016
Last Verified: June 2016